{"disease":{"id":"moderate-to-severe-ulcerative-colitis","name":"Moderate to Severe Ulcerative Colitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":8,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"upadacitinib","indication_name":"Moderately to severely active ulcerative colitis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"mirikizumab","indication_name":"Moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Omvoh","generic_name":"MIRIKIZUMAB","company_name":"Eli Lilly Nederland B.V.","drug_phase":"marketed","molecular_target":"Interleukin-23 subunit alpha","drug_class":"Interleukin-23 Antagonist [EPC]","quality_score":10,"revenue":"800","mechanism":"MIRIKIZUMAB blocks the activity of Interleukin-23, a protein involved in inflammation."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and fistulizing disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl3358920","indication_name":"moderately to severely active ulcerative colitis (UC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"ETRASIMOD","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Velsipity works by binding to and modulating the activity of certain immune cells in the body."},{"drug_id":"etrasimod","indication_name":"Moderate to severe ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etrasimod","generic_name":"etrasimod","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":64,"revenue":null,"mechanism":"Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes."},{"drug_id":"etrasimod","indication_name":"Induction of remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etrasimod","generic_name":"etrasimod","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":64,"revenue":null,"mechanism":"Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes."},{"drug_id":"etrasimod","indication_name":"Maintenance of clinical response and endoscopic remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etrasimod","generic_name":"etrasimod","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":64,"revenue":null,"mechanism":"Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes."},{"drug_id":"tnf-inhibitor","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and ankylosing spondylitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe non-radiographic axial spondyloarthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"mirikizumab-mrkz","indication_name":"Moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OMVOH","generic_name":"MIRIKIZUMAB-MRKZ","company_name":"ELI LILLY AND CO","drug_phase":"marketed","molecular_target":"Interleukin-23 subunit alpha","drug_class":"Interleukin-23 Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"velsipity","indication_name":"Moderate to severe ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"Etrasimod Arginine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":67,"revenue":null,"mechanism":"Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs."},{"drug_id":"velsipity","indication_name":"Induction of remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"Etrasimod Arginine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":67,"revenue":null,"mechanism":"Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs."},{"drug_id":"velsipity","indication_name":"Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"Etrasimod Arginine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":67,"revenue":null,"mechanism":"Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and ankylosing spondylitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and ankylosing spondylitis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and Crohn's disease and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and Crohn's disease and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and ankylosing spondylitis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and psoriatic arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ustekinumab-aekn","indication_name":"Moderately to Severely Active Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SELARSDI","generic_name":"USTEKINUMAB-AEKN","company_name":"ALVOTECH USA INC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and ankylosing spondylitis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and ankylosing spondylitis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and rheumatoid arthritis and ankylosing spondylitis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and rheumatoid arthritis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ulcerative colitis, and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, ulcerative colitis, and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, and atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, atopic dermatitis, and plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ustekinumab-auub","indication_name":"Moderately to Severely Active Ulcerative Colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"WEZLANA","generic_name":"USTEKINUMAB-AUUB","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"Interleukin-12 Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":163,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03221036","title":"Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":402,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT06589986","title":"A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06588855","title":"A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04879966","title":"A Cohort Study Comparing IFX to CS for Moderate to Severe UC","phase":"","overall_status":"UNKNOWN","enrollment_count":342,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT04090411","title":"A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":246,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04700449","title":"A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":145,"lead_sponsor_name":"Connect Biopharm LLC","has_results":true},{"nct_id":"NCT07535489","title":"Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":144,"lead_sponsor_name":"Nanjing Immunophage Biotech Co., Ltd","has_results":false},{"nct_id":"NCT07035041","title":"A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"InventisBio Co., Ltd","has_results":false},{"nct_id":"NCT07158242","title":"A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05486104","title":"Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":92,"lead_sponsor_name":"Ganzhou Hemay Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT07309744","title":"Universal CAR-T Cell Injection Targeting CD19/BCMA in Patients With Inflammatory Bowel Disease","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT06693908","title":"A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT03627052","title":"A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Incyte Corporation","has_results":false}],"total":13},"guidelines":[{"drug_id":"velsipity","guideline_body":"FDA label","recommendation":"VELSIPITY is indicated for the treatment of moderately to severely active ulcerative colitis in adults.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"velsipity","guideline_body":"FDA label","recommendation":"VELSIPITY is indicated for the treatment of moderately to severely active Crohn's disease in adults.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"etrasimod","guideline_body":"FDA label","recommendation":"VELSIPITY is indicated for the treatment of moderately to severely active ulcerative colitis in adults.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"etrasimod","guideline_body":"FDA label","recommendation":"VELSIPITY is indicated for the treatment of moderately to severely active Crohn's disease in adults.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}